|
Expression of amino-terminal ezrin inhibits metastasis of breast carcinoma cells |
|||||
| Cell linea |
Transfected with |
Primary tumour takes (%) |
Day of 1 cm tumour diameterb |
Day of sacrifice |
Metastasis (%)c |
|
|
|||||
| SP1 |
None |
100% (13/13) |
24 ± 7 |
35 |
23% (3/13) |
| AC2M2 |
None |
100% (11/11) |
30 ± 5 |
41 |
90% (10/11)† |
| pCB6 |
Vector |
100% (8/8) |
33 ± 4 |
39 |
88% (7/8) |
| WTC4 |
WT ezrin |
100% (7/7) |
28 ± 4 |
41 |
88% (6/7) |
| WTC6 |
WT ezrin |
100% (15/15) |
26 ± 2 |
39 |
87% (13/15) |
| NTC6 |
N-term ezrin |
38% (3/8) |
40 ± 10* |
47 |
0% (0/8)‡ |
| NTC7 |
N-term ezrin |
100% (8/8) |
28 ± 1 |
39 |
38% (3/8)‡ |
| NTB8d |
N-term ezrin |
100% (5/5) |
29 ± 3 |
41 |
0% (0/5)‡ |
|
aPoorly metastatic parental SP1 cells or highly metastatic variant AC2M2 cells alone, or transfected with empty pCB6 vector, or a vector encoding wild-type (WT) ezrin or amino-terminal (N-term) ezrin, were transplanted (7.5 × 103 cells) into the mammary fat pad of syngeneic mice (see text). bDay to 1 cm tumour diameter was calculated by linear regression analysis of data from individual mice. Values are expressed as mean ± standard deviation. Clone NTC6 showed a significant increase (*) in the day of 1 cm tumour diameter compared with WTC4 and WTC6 (P = 0.012). Mice with NTC6 tumours were therefore killed approximately 1 week later to allow tumour growth to a comparable size. cAC2M2 cells showed significantly more metastases than did the parental SP1 cells (†P = 0.003; Fisher's exact test). Pooled results from three N-term ezrin expressing clones showed a significant reduction in metastases compared with two WT ezrin expressing clones (‡P < 0.0001). Individual P values for NTC6, NTC7 and NTB8 are as follows (respectively): <0.0001, 0.002 and 0.002. dNTB8 is an N-term ezrin-expressing clone derived from an independent transfection of AC2M2 cells, and was transplanted as described above. | |||||
Elliott et al. Breast Cancer Research 2005 7:R365 doi:10.1186/bcr1006 |
|||||